About the Authors

  • The Authors and Contributors of "Patent Docs" are patent attorneys and agents, many of whom hold doctorates in a diverse array of disciplines.
2018 Juristant Badge - MBHB_165
Juristant #4 Overall Rank

E-mail Newsletter

  • Enter your e-mail address below to receive the "Patent Docs" e-mail newsletter.

Enter your email address:

Delivered by FeedBurner

Contact the Docs

Docs on Twitter


Disclaimer

  • "Patent Docs" does not contain any legal advice whatsoever. This weblog is for informational purposes only, and its publication does not create an attorney-client relationship. In addition, nothing on "Patent Docs" constitutes a solicitation for business. This weblog is intended primarily for other attorneys. Moreover, "Patent Docs" is the personal weblog of the Authors; it is not edited by the Authors' employers or clients and, as such, no part of this weblog may be so attributed. All posts on "Patent Docs" should be double-checked for their accuracy and current applicability.
Juristat_165
Juristat #8 Overall Rank

Pharma-50-transparent_216px_red

« University of Florida Research Foundation, Inc. v. General Electric Co. (Fed. Cir. 2019) | Main | Webinar on Functional Claiming for Mechanical and Electrical Arts »

February 28, 2019

Comments

Whether or not the claim construction includes the additional preamble phrase, this seems like a pyrrhic victory at best.

Let's say that the claim preamble "breathes life" into the claim, and thus it is a limitation.

Is it not -- though -- a meaningless one, vis a vis inherency?

20–25 mg/m2 of cabazitaxel in combination with prednisone or prednisolone is surely anticipated or at least obvious as a physical item...

The comments to this entry are closed.

August 2019

Sun Mon Tue Wed Thu Fri Sat
        1 2 3
4 5 6 7 8 9 10
11 12 13 14 15 16 17
18 19 20 21 22 23 24
25 26 27 28 29 30 31